Siltuximab (CNTO 328): a promising option for human malignancies
about
Proteomic-Based Approaches for the Study of Cytokines in Lung CancerFrom obesity to cancer: a review on proposed mechanisms.Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway.Role of interleukin-6 in cancer progression and therapeutic resistance.Tumor-Associated Macrophages as Target for Antitumor Therapy.How Signaling Molecules Regulate Tumor Microenvironment: Parallels to Wound Repair.Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases.Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.
P2860
Q26738539-1B0954FE-E328-4359-8444-2E4A18D883E0Q30241069-C9B2CD8C-8166-4ECE-80AC-AEFEB0C9F157Q36878675-4640AC98-B63F-424A-A3AA-52AF5A8359FDQ38853625-87107D9D-0CD6-4E42-B925-FF9CB9328A93Q39403895-8F550583-5C8E-4E34-906E-680FBD8BFAABQ47601253-9B86D361-5EC3-4972-B719-9BAAC1C06B3CQ48129259-EACAC478-40FB-49B8-81CD-637EDB712C20Q51825149-DC8B1EAE-6510-4794-8C3D-7DAE04407121Q52540247-1AB55420-E26B-413F-B2DB-C2B04C08EE12Q52560420-CBED198A-629E-40D5-BE83-E4BEFEB542F3Q55052878-61CA72B9-B509-4F29-B59F-69FFEB5F23CC
P2860
Siltuximab (CNTO 328): a promising option for human malignancies
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Siltuximab (CNTO 328): a promising option for human malignancies
@ast
Siltuximab (CNTO 328): a promising option for human malignancies
@en
Siltuximab (CNTO 328): a promising option for human malignancies
@nl
type
label
Siltuximab (CNTO 328): a promising option for human malignancies
@ast
Siltuximab (CNTO 328): a promising option for human malignancies
@en
Siltuximab (CNTO 328): a promising option for human malignancies
@nl
prefLabel
Siltuximab (CNTO 328): a promising option for human malignancies
@ast
Siltuximab (CNTO 328): a promising option for human malignancies
@en
Siltuximab (CNTO 328): a promising option for human malignancies
@nl
P2860
P921
P3181
P356
P1476
Siltuximab (CNTO 328): a promising option for human malignancies
@en
P2093
Bao-An Chen
Runzhe Chen
P2860
P304
P3181
P356
10.2147/DDDT.S86438
P407
P5008
P577
2015-07-02T00:00:00Z